Drug Trial Radar · NCT04853251
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Dec 14, 2021
Primary completion
Jul 30, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Apr 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
PDS Implant With Ranibizumab 100 mg/mlDevice
Ranibizumab 100 mg/mL will be delivered via PDS
LUCENTIS (Ranibizumab Injection)Drug
Ranibizumab (0.5 mg intravitreal \[IVT\] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Corneal Endothelial Cell Density (ECD) From Baseline at Week 48 in the Study Eye as Compared With the Fellow Eye, as Assessed by Specular MicroscopyTime frame: Baseline, Week 48
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
California Retina Consultants
Bakersfield, California
Retina Associates of Southern California
Huntington Beach, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retinal Consultants Med Group
Sacramento, California
University of California San Francisco
San Francisco, California
Orange County Retina Med Group
Santa Ana, California
Macula Retina Vitreous Research Institute
Torrance, California
Southwest Retina Consultants
Durango, Colorado
Advanced Vision Research Institute
Longmont, Colorado
Retina Specialty Institute
Pensacola, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Southeast Retina Center
Augusta, Georgia
University Retina and Macula Associates, PC
Lemont, Illinois
Maine Eye Center
Portland, Maine
The Retina Care Center
Baltimore, Maryland
Wilmer Eye Institute Johns Hopkins University
Baltimore, Maryland
Cumberland Valley Retina Consultants PC
Hagerstown, Maryland
Associated Retinal Consultants PC
Royal Oak, Michigan
VitreoRetinal Surgery, PLLC.
Minneapolis, Minnesota
Midwest Vision Research Foundation
Chesterfield, Missouri
Sierra Eye Associates
Reno, Nevada
Envision Ocular, LLC
Bloomfield, New Jersey
Seeta Eye Centers
Poughkeepsie, New York
Duke Eye Center
Durham, North Carolina
Graystone Eye-Hickory - 2415 Century Pl
Hickory, North Carolina
Fargo Retina Consultants
Fargo, North Dakota
Cincinnati Eye Institute
Blue Ash, Ohio
Cleveland Clinic
Cleveland, Ohio
Erie Retina Research
Erie, Pennsylvania
Charles Retina Institute
Germantown, Tennessee
Tennessee Retina PC
Nashville, Tennessee
Panhandle Eye Group LLP Southwest Retina Specialists
Amarillo, Texas
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Retina Consultants of Texas
Schertz, Texas
Retina Associates of Utah, PLLC
Salt Lake City, Utah
Piedmont Eye Center
Lynchburg, Virginia
Wagner Kapoor Institute
Norfolk, Virginia
Spokane Eye Clinical Research
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.